Want to see MEDP full AI Analyst Report?
MEDP Stock Chart & Stats
$520.60
$7.21(2.08%)
At close: 4:00 PM EST
$520.60
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$306.70 - $628.92
Previous CloseN/A
Volume64.09K
Average Volume (3M)297.95K
Market Cap
$15.36B
Enterprise Value$13.40K
Total Cash (Recent Filing)$652.68M
Total Debt (Recent Filing)$122.26M
Price to Earnings (P/E)32.5
Beta1.08
Next Earnings
Jul 22, 2026EPS Estimate
3.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.24
Shares Outstanding28,559,689
10 Day Avg. Volume285,053
30 Day Avg. Volume297,955
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$472.89Price Target Upside-9.16% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)16.99
Revenue Forecast (FY)$2.78B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMedpace’s very strong trailing‑12‑month free cash flow (~$745M) and near‑one‑to‑one conversion with net income indicate high earnings quality and durable internal funding. This supports reinvestment in operations, working capital flexibility, debt service, and strategic optionality over the next several quarters.
Profitability And MarginsSustained, industry‑leading operating margins alongside multi‑year revenue growth reflect scalable service delivery and pricing power in complex therapeutic areas. Robust EBIT and net margins provide buffer versus cyclical revenue swings, supporting long‑term cash generation and the ability to fund SG&A, R&D support, and strategic investments.
Backlog Visibility And Near-term ConvertibilityA multi‑billion dollar backlog with a sizable portion forecast to convert within 12 months gives predictable revenue runway and operational cadence. This contractual visibility supports capacity planning, revenue recognition stability, and near‑term cash flows, making topline delivery less dependent on immediate new bookings.
Bears Say
Elevated Cancellations / Book‑to‑billRising cancellations and a below‑unity net book‑to‑bill reduce revenue predictability and weaken backlog replenishment. If cancellations persist, the company may face lumpy revenue recognition, underutilized capacity and slower organic growth, pressuring multi‑quarter top‑line momentum and the convertibility assumption of current backlog.
Declining Longer‑term Backlog CoverageA sustained drop in beyond‑12‑month backlog coverage reduces visibility into medium‑term revenue streams and undermines multi‑year planning. This trend signals potential weakening of pipeline depth or timing shifts in awards that can materially affect growth beyond the next 12 months and complicate strategic resource allocation.
Weaker RFP / New Opportunity ActivityLower RFP volumes indicate softer new opportunity flow, which can erode future award rates even if win rates remain solid. Persistently weaker RFP activity will limit backlog replenishment over multiple quarters, making revenue growth more reliant on existing contracts and heightening sensitivity to cancellations or timing shifts.
Medpace Holdings News
![Medpace Backs Phase 2 Cancer Imaging Trial With [68Ga]BED003](https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-150x150.jpg)
MEDP FAQ
What was Medpace Holdings Inc’s price range in the past 12 months?
Medpace Holdings Inc lowest stock price was $306.70 and its highest was $628.91 in the past 12 months.
What is Medpace Holdings Inc’s market cap?
Medpace Holdings Inc’s market cap is $15.36B.
When is Medpace Holdings Inc’s upcoming earnings report date?
Medpace Holdings Inc’s upcoming earnings report date is Jul 22, 2026 which is tomorrow.
How were Medpace Holdings Inc’s earnings last quarter?
Medpace Holdings Inc released its earnings results on Apr 22, 2026. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.921 by $0.359.
Is Medpace Holdings Inc overvalued?
According to Wall Street analysts Medpace Holdings Inc’s price is currently Overvalued.
Does Medpace Holdings Inc pay dividends?
Medpace Holdings Inc does not currently pay dividends.
What is Medpace Holdings Inc’s EPS estimate?
Medpace Holdings Inc’s EPS estimate is 3.98.
How many shares outstanding does Medpace Holdings Inc have?
Medpace Holdings Inc has 28,559,689 shares outstanding.
What happened to Medpace Holdings Inc’s price movement after its last earnings report?
Medpace Holdings Inc reported an EPS of $4.28 in its last earnings report, beating expectations of $3.921. Following the earnings report the stock price went down -22.625%.
Which hedge fund is a major shareholder of Medpace Holdings Inc?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$472.89 (-9.16% Downside)
$472.89 (-9.16% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 318.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.24%
Trailing 12-Months
Company Description
Medpace Holdings Inc
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
MEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$472.89
▼(-9.16% Downside)
Technical Analysis
Ownership Overview
19.42% Insiders
21.34% Mutual Funds
3.11% Other Institutional Investors
34.10% Public Companies and
Individual Investors